The two new awardees are LymphGuide and HEXASpec, which were selected from 26 applications. Each company received an $100,000 grant. Photo courtesy of The Ion

Rice University has doled out another batch of grants from its program supporting lab-based innovations.

The One Small Step Grant, which was announced a year ago and gave out its first grants in February, was established to fund Rice-founded, lab-stage projects on their path to commercialization

“The One Small Step Grant invites applications from students and faculty who are tackling some of the world’s most pressing challenges and preparing to bring their innovative technologies to market,” Nafisa Istami, innovation manager at Rice, says in a news release. “We received highly competitive applications from across campus, truly showcasing the growing momentum of technology innovation happening at Rice.”

The two new awardees are LymphGuide and HEXASpec, which were selected from 26 applications. Each company received an $100,000 grant.

LymphGuide was developed by Martha Fowler in Rice professor Omid Veiseh’s lab. The hydrogel platform is a customizable alginate that's combined with an engineered cell therapy to aid in lymphatic cell regrowth, initially targeting the treatment and prevention of lymphedema.

"We are profoundly grateful to the One Small Step Grant for supporting our vision to treat lymphedema,” says Martha Fowler, cofounder of LymphGuide. “This funding will propel our biotechnology into pre-clinical evaluation to make a meaningful impact in scientific research and for people suffering from lymphatic disease.” Fowler is also an active contributor in the Rice entrepreneurship ecosystem and an Liu Idea Lab of Innovation and Entrepreneurship Innovation Fellows Cohort 2 member.

Led by by Tianshu Zhai in Rice professor Jun Lou’s lab, HEXASpec develops inorganic fillers and molding compounds for next-generation chip packaging. Zhai is also one of the Liu Idea Lab of Innovation and Entrepreneurship Innovation Fellows.

“We are thrilled to receive the One Small Step Grant from Rice Innovation,” says Tianshu Zhai, cofounder of HEXASpec. “This support is crucial for advancing HEXASpec and signifies the strong backing of the Rice entrepreneurship community. We’re grateful for the opportunity to develop our technology with such robust support.”

The next round of grant opportunities will open next month with an online application process.

“The One Small Step Grant program is a demonstration of Rice’s commitment to supporting the commercialization of Rice technologies,” says Adrian Trömel, associate vice president of Innovation Strategy and Investments. “Each cycle further highlights the impactful work of Rice students and faculty to solve global problems across industries.”

Ten individuals from Rice University have been named to the second cohort of the Innovation Fellowship program. Photos via Rice.edu

10 Houston researchers named to fellowship to advance innovation

owls taking flight

A program with a mission to translate research into innovative startups has named its 2023 cohort of fellows.

Rice University's Innovation Fellows program, which is run by the Liu Idea Lab for Innovation and Entrepreneurship and the Office of Innovation, has announced the 10 innovators that will be joining the program this year. The program, open to Rice faculty and doctoral and postdoctoral students, provides support — funding, mentorship, and more — to move innovation out of labs and into commercialization.

“The Rice Innovation Fellows program is a critical part of our efforts to support innovation and entrepreneurship,” Rice President Reginald DesRoches says in a news release. “These exceptional individuals represent some of the most innovative and promising research being conducted at Rice, and we’re thrilled to support them as they work to bring their ideas to the world.”

According to the release, the 10 members of the 2023 cohort are:

  • Martha Fowler, a doctoral student from the bioengineering lab of Omid Veiseh
  • Carson Cole, a doctoral student from the chemistry lab of Jeff Hartgerink
  • Fatima Ahsan, a doctoral student from the electrical and computer engineering lab of Behnaam Aazhang
  • Siraj Sidhik, a doctoral student from the materials science and nanoengineering lab of Aditya Mohite
  • Roman Zhuravel, a postdoctoral student from the physics and astronomy lab of Guido Pagano
  • Samira Aghlara-Fotovat, a doctoral student from the bioengineering lab of Veiseh
  • Clarke Wilkirson, a doctoral student from the mechanical engineering lab of Peter Lillehoj
  • Yuren Feng, a doctoral student from the civil and environmental engineering lab of Qilin Li
  • Yang Xia, a doctoral student from the chemical and molecular engineering lab of Haotian Wang
  • Thao Vy Nguyen, a doctoral student from the chemical engineering lab of Sibani Lisa Biswal

Each of Rice's Innovation Fellows will receive up to $20,000 in funding, as well as access to the university's network for mentorship and training.

“We're incredibly excited to welcome this exceptional group of researchers into the Innovation Fellows program,” says Yael Hochberg, head of the Rice Entrepreneurship Initiative and faculty director for Lilie, in the release. “We look forward to working with them as they bring their groundbreaking research to market and make a real impact on the world.”

Last year's inaugural cohort in raised more than $1 million in venture capital funding and over $3 million in additional nondilutive funding, as well as earning more than $500,000 in revenue.

Some of the 2022 cohort's accomplishments included Helix Earth Technologies winning the inaugural TEX-E Prize and Sygne Solutions securing second place and $200,000 at the 2023 Rice Business Plan Competition.

Paul Cherukuri, Rice’s vice president for innovation, who recently joined the Houston Innovators Podcast, explains how this is one avenue Rice has for getting innovation off campus and into industry.

“With commercialization of research at the forefront of what Rice University wants to do,” says Cherukuri, "the Innovation Fellows program is the first in a constellation of programs and resources developed by the Office of Innovation to help impactful new ventures overcome the hard tech ‘valley of death’ and transition from the campus to the community, so we can help create the next generation of game-changing company for Houston, Texas and the world,."

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

New UH survey reveals concerns over AI data center growth in Houston

data findings

A new report out of the University of Houston shows that area residents remain wary of the long-term effects of operating data centers.

The recent survey from the University of Houston’s latest SPACE City Panel, conducted by the Center for Public Policy at the Hobby School of Public Affairs, shows that while 85 percent of Houston-area residents use AI, nearly 63 percent oppose the construction of AI data centers within 1 mile of their homes.

Respondents’ concerns centered around data centers’ high energy demand and the area’s power grid reliability. According to the survey, 32 percent of residents who oppose local data center projects would be more likely to support the centers if they relied on renewable energy over fossil fuels.

“Respondents understand that AI can bring economic and educational benefits, but they are also concerned about the physical infrastructure needed to fuel AI, especially data centers,” Soran Mohtadi, post-doctoral fellow at the Hobby School and a researcher on the report, said in a news release. “This physical infrastructure demands more electricity and water, leading to environmental impacts.”

Experts estimate that 6.5 gigawatts of data center capacity will be added to the Texas grid by 2030. And Houston’s data center capacity is predicted to more than double by 2028.

The Electric Reliability Council of Texas also projects electricity demand could reach 218 gigawatts by 2031, which would be more than double the record peak set in August 2023. Data centers are expected to account for 86 gigawatts of that new demand.

Survey respondents also said they are concerned about the state's future water supply, given the large amounts of water that data centers need to stay cool.

In terms of who’s responsible for that issue, 57.6 percent of respondents said they put the onus on Texas lawmakers, while 31.5 percent say tech companies should be responsible.

Additionally, more than 75 percent of respondents believed that data center developers and technology companies—not residents—should bear the cost of infrastructure upgrades to support data centers.

“Every decision legislators make has implications on residents’ everyday lives and local infrastructure now and in the future,” Maria P. Perez Arguelles, lead researcher on the report and research assistant professor at the Hobby School, added in the news release. “This issue is going to become more important in years to come, so this is just the beginning.”

Read the full report here.

Houston-born Cemvita makes breakthrough in sustainable fuel production

clean fuels

Houston-based biotech company Cemvita announced that it recently reached a critical milestone in the development of its FermOil product, which can be used to create Sustainable Aviation Fuel (SAF) and other renewable fuels at industrial scale.

The company shared in a news release that it completed a 75,000-liter industrial fermentation run at Belgium's Bio Base Europe Pilot Plant.

The campaign achieved target technical metrics for the production of FermOil, Cemvita’s renewable natural oil (RNO). FermOil is produced from industrial crude glycerin, an industrial byproduct, as opposed to traditional sugar-based feedstocks used in many bio-oil fermentation processes. It's designed to be a drop-in feedstock for creating SAFs.

Cemvita had previously advanced its FermOil production process through multiple scale-up stages before successfully reaching the 75,000-liter demonstration campaign, according to the company.

“This is not just a fermentation milestone,” Moji Karimi, CEO at Cemvita, said in the release. “It is a blueprint for how existing industrial infrastructure can evolve into circular bioeconomy infrastructure. Every biodiesel plant generating crude glycerin is a potential platform for renewable natural oil production.”

The milestone also supports the deployment of Cemvita’s industrial biomanufacturing platform, FermWorks, which integrates with existing energy and industrial infrastructure to turn waste carbon streams into SAFs and other materials. According to the release, Cemvita plans to move forward with commercial deployment discussions with partners in Brazil, Europe and in the UK. Cemvita already has a partnership with the Brazilian sustainable research institution REMA.

“We are proud to support innovative companies like Cemvita in scaling breakthrough industrial biotechnology solutions,” Hendrik Waegeman, head of business operations at Bio Base Europe Pilot Plant, added in the release. “Successfully operating at the 75,000-liter scale using a feedstock such as crude glycerin highlights both the maturity of the technology and the quality of the scale-up execution achieved by the Cemvita team.”

---

This article originally appeared on our sister site, EnergyCapitalHTX.com.

Eli Lilly scoops up Houston biotech startup in $300 million deal

big pharma deal

Pharmaceutical giant Eli Lilly has acquired Houston biotech startup CrossBridge Bio, which develops antibody-drug conjugates for cancer, in a deal worth up to $300 million. The deal was celebrated by TMC Venture Fund and the University of Texas Health Science Center at Houston last week.

CrossBridge, founded in 2023, is developing ADCs based on research by Kyoji Tsuchikama and Zhiqiang An, both of UT Health Houston. Tsuchikama is an associate professor of medicinal chemistry and a globally recognized ADC pioneer, and An is a professor of molecular science and vice president of drug discovery.

Antibody-drug conjugates (ADCs) are a potent combination of targeted therapy and chemotherapy that kills cancer cells while saving healthy tissue.

Clinical trials for CrossBridge’s primary ADC candidate, CBB-120, are expected to start this year, pending approval from the U.S. Food and Drug Administration (FDA).

“I’m proud of how well our team has executed and advanced our platform in such a short time since the company’s founding,” Michael Torres, co-founder and CEO of CrossBridge, said in a news release. “By becoming a part of Lilly, a leader in patient-focused therapeutic development, we are well-positioned to further accelerate the clinical potential of this approach.”

Under the Lilly deal, CrossBridge shareholders were expected to receive an upfront payment along with a follow-up payment based on the achievement of certain milestones.

In 2024, CrossBridge closed a $10 million seed round. Among the investors in CrossBridge are the Texas Medical Center Venture Fund, CE-Ventures, Alexandria Venture Investments, Portal Innovations, Linden Lake Labs, and the Cancer Prevention and Research Institute of Texas (CPRIT). It was formed in TMC Innovation’s Accelerator for Cancer Therapeutics program."Built within the TMC ecosystem, CrossBridge Bio grew with the support, funding, and resources that helped shape its trajectory. TMC led the company's early financing and watched it evolve from its earliest days to its acquisition by Eli Lilly," William McKeon, president and CEO of the Texas Medical Center, shared in a LinkedIn post. "[This is a] strong reminder that breakthrough science and the right early backing can change what’s possible."